Prospect Capital Corporation 6. PBC
Set alert
As of Apr 24, 3:47 PM ET
- Open
- 25.05
- Prev close
- 25.06
- Mkt cap
- 0
- Vol
- 12.76K
- Avg vol
- 9.71K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.05
- High
- 25.06
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 25.31
- 200-d avg
- 25.61
News
1 week ago gurufocus.com
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical ValuePR NewswireSH
3 weeks ago gurufocus.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:
1 month ago gurufocus.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at
1 month ago globenewswire.com
Safe Harbor Institutional Named Top Business Solutions Company at 2026 PBC Cannabis Banking Conference
Industry recognition highlights Safe Harbor's expertise in helping banks and credit unions build, strengthen and scale cannabis banking programs Industry recognition highlights Safe Harbor's…
1 month ago seekingalpha.com
Once Upon A Farm, PBC (OFRM) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Once Upon A Farm, PBC (OFRM) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
1 month ago marketbeat.com
Planet Labs PBC Q2 Earnings Call Highlights
Planet Labs PBC NYSE: PL reported record second-quarter revenue of $116 million, up approximately 58% from a year earlier, as satellite services execution and demand from defense and intelligence…
2 months ago marketbeat.com
Zevia PBC Q2 Earnings Call Highlights
Zevia PBC NYSE: ZVIA reported second-quarter 2026 net sales of $45 million, up 1.1% from the prior-year period, as pricing actions helped offset comparisons affected by prior-year customer load-ins…
2 months ago seekingalpha.com
Once Upon A Farm, PBC (OFRM) Q2 2026 Earnings Call Transcript
Once Upon A Farm, PBC (OFRM) Q2 2026 Earnings Call Transcript
3 months ago fool.com
Planet Labs PBC vs. Snowflake: Is a Space Stock or AI Cloud Stock the Better Buy in 2026?
Planet Labs PBC maintains a unique constellation of over 200 satellites providing daily Earth-imaging data for government and commercial clients. Snowflake operates a leading cloud-native data…
3 months ago marketbeat.com
Planet Labs PBC Shareholders Back Directors, KPMG and Pay Plan at Annual Meeting
Planet Labs PBC NYSE: PL held its 2026 annual meeting of stockholders virtually on July 9, with shareholders voting on three company proposals, according to the meeting transcript.
4 months ago gurufocus.com
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
5 months ago marketbeat.com
Planet Labs PBC Q1 Earnings Call Highlights
Planet Labs PBC NYSE: PL reported record first-quarter fiscal 2027 revenue and raised its full-year sales outlook, citing strong demand from defense and intelligence customers, international…
5 months ago gurufocus.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
5 months ago businesswire.com
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that…
5 months ago gurufocus.com
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
5 months ago businesswire.com
Planet Labs PBC Receives John Deere Sustainability Award
SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC has been selected as a recipient of a John Deere supplier Sustainability award for 2025. The award is presented to a select group of suppliers globally…
5 months ago gurufocus.com
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai
5 months ago gurufocus.com
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir
5 months ago businesswire.com
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of…
7 months ago globenewswire.com
National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men's Pre-Conception Health Complete Multivitamin Claims
Following a challenge brought by OLLY PBC, BBB National Programs' National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men's…